Can Redwire's Microgravity Pharma Work Create New Revenue Streams?
Redwire Corporation RDW is expanding its microgravity capabilities beyond traditional space infrastructure into pharmaceutical research and development. The company’s Pharmaceutical In-Space Laboratory – Bio-crystal Optimization Experiment (PIL-BOX) enables pharmaceutical companies and researchers to use microgravity to grow crystals of protein-based pharmaceuticals and other key molecules. Redwire had launched 42 PIL-BOXes through Dec. 31, 2025, highlighting the growing adoption of its technology for space-based pharmaceutical research.
Microgravity provides conditions different from those available on Earth, potentially allowing certain products and materials to be produced with enhanced or differentiated properties. In pharmaceutical applications, Redwire’s platform focuses on growing protein crystals that can support drug development. This gives the company an opportunity to provide specialized space-based research capabilities while expanding the applications of its microgravity business.
An important development is Redwire’s move toward a commercial model that extends beyond providing research infrastructure. During 2025, the company entered into a licensing agreement with ExesaLibero Pharma, under which Redwire is entitled to receive royalties from commercial sales of resulting pharmaceutical products. This arrangement provides a potential avenue for Redwire to participate in the economic value generated by products developed using its microgravity capabilities.
The combination of an established PIL-BOX platform, increasing launches and a royalty-based licensing arrangement could broaden Redwire’s role in pharmaceutical development. As microgravity research moves toward commercial applications, Redwire could generate additional value from its space-based biotechnology capabilities and expand the commercial potential of its space business.
Companies Exploring Microgravity for Drug Development
The use of microgravity for pharmaceutical research is also attracting major drug developers. Bristol Myers Squibb BMY and Eli Lilly and Company LLY are exploring advanced research approaches aimed at improving drug development and pharmaceutical formulations.
Bristol Myers Squibb has conducted protein-crystallization experiments in microgravity to study larger and more uniform protein crystals that may support drug development.
Eli Lilly maintains a broad research and development platform focused on developing medicines and advancing complex pharmaceutical science.
Earnings Estimates for RDW Stock
The Zacks Consensus Estimate for 2026 and 2027 earnings per share suggests year-over-year growth of 57.32% and 40%, respectively.
Image Source: Zacks Investment Research
RDW Stock Is Trading at a Premium
Redwire is trading at a premium relative to the industry, with a forward 12-month price-to-sales of 4.94X compared with the industry average of 2.11X.
Image Source: Zacks Investment Research
RDW Stock Price Performance
Over the past six months, RDW shares have risen 11.4% against the industry’s 18.3% fall.
Image Source: Zacks Investment Research
RDW’s Zacks Rank
Redwire currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpRedwire Corporation (RDW) : Free Stock Analysis Report
Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
